Hong Kong Pharma Stock Performance
| HKPD Stock | 0.83 0.02 2.47% |
The company retains a Market Volatility (i.e., Beta) of 0.54, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Hong Kong's returns are expected to increase less than the market. However, during the bear market, the loss of holding Hong Kong is expected to be smaller as well. At this point, Hong Kong Pharma has a negative expected return of -0.49%. Please make sure to check out Hong Kong's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Hong Kong Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Hong Kong Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | How Traws Pharma Inc. stock reacts to inflationary pressures - Gap Down Weekly Stock Performance Updates - Fundao Cultural do Par | 11/14/2025 |
2 | Is JanAushadi threat to Branded pharma industry - Market Sentiment Surveys Turn Market Volatility into Wealth - Bollywood Helpline | 12/16/2025 |
3 | Annual Review Volume and Amount Rise Together Hong Kong stocks lead the world in new stock fundraising in 2025, with pharmaceutical stocks in high demand Changf... | 12/19/2025 |
4 | Hong Kong Stock Market Pharma 2025 IPO Surge, Strong Subscription Demand, and Policy Reforms Provide Powerful Boost Year-End Review - | 12/24/2025 |
5 | AI biotech Insilico pulls off Hong Kong debut - FirstWord Pharma | 12/30/2025 |
6 | Hong Kong Stocks Close Mixed Ascletis Pharma Receives U.S. Nod to Begin Phase II Trial of ASC30 - marketscreener.com | 01/05/2026 |
7 | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency | 01/16/2026 |
8 | Catalyst Pharmaceuticals, Inc. CPRX Shares Bought by Y Intercept Hong Kong Ltd - MarketBeat | 01/27/2026 |
9 | GIC Private Limited initiated a stake in Ascletis Pharma by 64,128,000 shares at a price of HKD 12.18 per share - TradingView | 02/06/2026 |
| Begin Period Cash Flow | 627.3 K | |
| Total Cashflows From Investing Activities | -2.5 M |
Hong Kong Relative Risk vs. Return Landscape
If you would invest 120.00 in Hong Kong Pharma on November 10, 2025 and sell it today you would lose (37.00) from holding Hong Kong Pharma or give up 30.83% of portfolio value over 90 days. Hong Kong Pharma is currently does not generate positive expected returns and assumes 4.4267% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Hong, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hong Kong Target Price Odds to finish over Current Price
The tendency of Hong Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.83 | 90 days | 0.83 | about 63.79 |
Based on a normal probability distribution, the odds of Hong Kong to move above the current price in 90 days from now is about 63.79 (This Hong Kong Pharma probability density function shows the probability of Hong Stock to fall within a particular range of prices over 90 days) .
Hong Kong Price Density |
| Price |
Predictive Modules for Hong Kong
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Hong Kong Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Hong Kong Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Hong Kong is not an exception. The market had few large corrections towards the Hong Kong's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Hong Kong Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Hong Kong within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.59 | |
β | Beta against Dow Jones | 0.54 | |
σ | Overall volatility | 0.17 | |
Ir | Information ratio | -0.14 |
Hong Kong Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Hong Kong for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Hong Kong Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Hong Kong Pharma generated a negative expected return over the last 90 days | |
| Hong Kong Pharma has some characteristics of a very speculative penny stock | |
| Hong Kong Pharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 20.31 M. Net Loss for the year was (27.06 K) with profit before overhead, payroll, taxes, and interest of 2.42 M. | |
| Hong Kong Pharma has a strong financial position based on the latest SEC filings | |
| Latest headline from news.google.com: GIC Private Limited initiated a stake in Ascletis Pharma by 64,128,000 shares at a price of HKD 12.18 per share - TradingView |
Hong Kong Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Hong Stock often depends not only on the future outlook of the current and potential Hong Kong's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Hong Kong's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 10.2 M | |
| Cash And Short Term Investments | 3 M |
Hong Kong Fundamentals Growth
Hong Stock prices reflect investors' perceptions of the future prospects and financial health of Hong Kong, and Hong Kong fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hong Stock performance.
| Return On Equity | -0.0059 | ||||
| Return On Asset | 0.0132 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 8.39 M | ||||
| Shares Outstanding | 11 M | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 20.31 M | ||||
| Gross Profit | 2.42 M | ||||
| EBITDA | 1.21 M | ||||
| Net Income | (27.06 K) | ||||
| Total Debt | 2.37 M | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | 569.21 K | ||||
| Market Capitalization | 9.1 M | ||||
| Total Asset | 9.42 M | ||||
| Retained Earnings | 1.5 M | ||||
| Working Capital | 5.81 M | ||||
About Hong Kong Performance
By analyzing Hong Kong's fundamental ratios, stakeholders can gain valuable insights into Hong Kong's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Hong Kong has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hong Kong has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 10.28 | 11.86 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Equity | (0.01) | (0.01) |
Things to note about Hong Kong Pharma performance evaluation
Checking the ongoing alerts about Hong Kong for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hong Kong Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hong Kong Pharma generated a negative expected return over the last 90 days | |
| Hong Kong Pharma has some characteristics of a very speculative penny stock | |
| Hong Kong Pharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 20.31 M. Net Loss for the year was (27.06 K) with profit before overhead, payroll, taxes, and interest of 2.42 M. | |
| Hong Kong Pharma has a strong financial position based on the latest SEC filings | |
| Latest headline from news.google.com: GIC Private Limited initiated a stake in Ascletis Pharma by 64,128,000 shares at a price of HKD 12.18 per share - TradingView |
- Analyzing Hong Kong's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hong Kong's stock is overvalued or undervalued compared to its peers.
- Examining Hong Kong's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hong Kong's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hong Kong's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hong Kong's stock. These opinions can provide insight into Hong Kong's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Hong Stock analysis
When running Hong Kong's price analysis, check to measure Hong Kong's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hong Kong is operating at the current time. Most of Hong Kong's value examination focuses on studying past and present price action to predict the probability of Hong Kong's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hong Kong's price. Additionally, you may evaluate how the addition of Hong Kong to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |